Clinical effect of Bilwadi Agad in fungal infection.

Role of Bilwadi Agad with and without Kushthaghna Mahakashay in Dadru w.s.r. to Tinea infection: A comparative clinical study.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/03/024345

Enrollment

Registered

2020-03-30

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Group A-Kushthghna Mahakashay Tab. : Group A â??15 Patients included in this group will be given Kushthghna Mahakashay tablet . Group A:Kushthghna Mahakashay Tab. Dose: 2 Tablets of 500

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients of age between 18 and 60 years. 2) Patients having classical symptoms of Dadru. 3) Patients having the symptoms of Tinea corporis and Tinea cruris. 4) Patient who will give informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients having symptoms of other Tinea infection except tinea corporis and tinea cruris. 2) Patients of Tinea having secondary infections. 3) Patients suffering with Diabetes mellitus. 4) Patients of other skin diseases. 5) Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Changes in clinical manifestation of Dadru w.s.r.to Tinea infection.Timepoint: 30 days	—

Secondary

Measure	Time frame
Changes in parameters of Dadru w.s.r.to Tinea infectionTimepoint: One month	—

Countries

India

Contacts

Public ContactDr Narsingh Patel

National institute of ayurveda, Jaipur

dramolkaduayu@gmail.com8725948131

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026